MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/jhbp.70056

Медицинская библиотека · Journal of hepato-biliary-pancreatic sciences · 2026

Multicenter Validation Study of the Clinical Diagnostic Criteria for IgG4-Related Sclerosing Cholangitis 2020 in Japan.

Naitoh Itaru, Nakazawa Takahiro, Kubota Kensuke, Nishino Takayoshi, Nakamura Akira, Inoue Dai, Sano Takanori, Kikuta Kazuhiro, Kurita Yusuke, Chiba Kazuro, Ikeura Tsukasa, Matsubayashi Hiroyuki, Ishikawa Takuya, Kuwatani Masaki, Kamisawa Terumi, Yasuda Ichiro, Kawano Mitsuhiro, Masamune Atsushi, Japan Pancreatitis Study Group

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеВалидационное исследованиеПеревод в очереди

Аннотация

BACKGROUND

The diagnostic performance of clinical diagnostic criteria for IgG4-related sclerosing cholangitis 2020 (IgG4-SC2020) has not been fully validated since its proposal as a revision of the 2012 criteria (IgG4-SC2012).

METHODS

We conducted a multicenter validation study to evaluate the diagnostic performance of IgG4-SC2020 using clinical data collected from 1034 patients with IgG4-SC and 447 patients with mimickers, including 143 with pancreatic cancer, 157 with primary sclerosing cholangitis, and 147 with cholangiocarcinoma in Japan.

RESULTS

The sensitivity of IgG4-SC2020 was significantly higher than that of IgG4-SC2012 (99.0% vs. 89.1%; p < 0.001). The specificities of both IgG4-SC2020 and IgG4-SC2012 were 100% for pancreatic cancer and cholangiocarcinoma. For primary sclerosing cholangitis, the specificities of IgG4-SC2020 and IgG4-SC2012 were 97.5% and 100%, respectively, with no significant difference (p = 0.123). A total of 113 patients who could not be diagnosed according to the IgG4-SC2012 were successfully diagnosed using IgG4-SC2020. These diagnostic improvements were attributed to the inclusion of MRCP findings (n = 97), the absence of neoplastic cells on histology (n = 15), and the presence of IgG4-related kidney lesions (n = 1).

CONCLUSIONS

This Japanese multicenter validation study demonstrated that the diagnostic performance of IgG4-SC2020 was superior to that of IgG4-SC2012.

TRIAL REGISTRATION: UMIN Clinical Trials Registry (UMIN-CTR), UMIN000052984.

Для цитирования: Naitoh Itaru, Nakazawa Takahiro, Kubota Kensuke, Nishino Takayoshi, Nakamura Akira, Inoue Dai, Sano Takanori, Kikuta Kazuhiro, Kurita Yusuke, Chiba Kazuro, Ikeura Tsukasa, Matsubayashi Hiroyuki, Ishikawa Takuya, Kuwatani Masaki, Kamisawa Terumi, Yasuda Ichiro, Kawano Mitsuhiro, Masamune Atsushi, Japan Pancreatitis Study Group. Multicenter Validation Study of the Clinical Diagnostic Criteria for IgG4-Related Sclerosing Cholangitis 2020 in Japan.. Journal of hepato-biliary-pancreatic sciences. 2026. DOI: 10.1002/jhbp.70056.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.